Forward P/E ratios in Eli Lilly stock forecast 2030 scenarios remain elevated relative to the S&P 500, reflecting investor pricing of robust growth potential and low cyclicality risk in pharma earnings. While Lilly is working through supply chain issues as it ramps up production of its GLP drugs, profits are already rolling in. Overall revenue for the drug company jumped 26 percent during the first quarter of 2024 compared to the same time last year. It’s now one of the best-performing stocks in the S&P 500 for the year. However, any revenue growth deceleration, mishaps with drugs, and rising competition can derail this forecast. Eli Lilly stock forecast 2030 benefits from currency-hedged global expansion, particularly in emerging markets where healthcare infrastructure investment is accelerating demand for branded treatments.
